Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 10/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | NPC1 | O15118 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19801128 | 0.81 | ALDH1A1 (0.40) | S1PR1S1PR3RAB9AALDH1A1NPC1 | |
| SCHEMBL14235588 | 0.80 | — | — | |
| SCHEMBL28599955 | 0.77 | S1PR1 (0.44) | S1PR1S1PR3RAB9AALDH1A1NPC1 | |
| SCHEMBL24346840 | 0.74 | DAO (0.35) | RAB9AALDH1A1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL29955129 | 0.74 | ACHE (0.32) | S1PR1S1PR3MAPTLMNA | |
| SCHEMBL309854 | 0.74 | — | — | |
| SCHEMBL10154815 | 0.73 | RAB9A (0.46) | S1PR1S1PR3RAB9AALDH1A1NPC1 | |
| SCHEMBL1162479 | 0.72 | VHL (0.50) | S1PR1S1PR3RAB9AALDH1A1NPC1 | |
| SCHEMBL10120992 | 0.72 | S1PR1 (0.45) | S1PR1S1PR3RAB9AALDH1A1NPC1 | |
| SCHEMBL3763783 | 0.72 | S1PR1 (0.39) | S1PR1S1PR3RAB9AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | S1PR1 454/4885S1PR3 514/4885RAB9A 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.